Prostate‐specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer-Reference-Cited by-同舟云学术

Prostate‐specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer

Published:2022-07-12 Issue:S3 Volume:130 Page:8-10
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU International

Author:

O’Brien Jonathan S.¹²³^ORCID,McVey Aoife¹,Kelly Brian D.¹²^ORCID,Jenjitranant Pocharapong¹,Buteau James⁴,Hofman Michael S.²⁴^ORCID,Kasivisvanithan Veeru¹⁵,Eapen Renu¹²,Moon Daniel¹²^ORCID,Murphy Declan G.¹²^ORCID,Lawrentschuk Nathan¹²³⁶^ORCID

Affiliation:

1. Division of Cancer Surgery Peter MacCallum Cancer Centre Melbourne Victoria Australia

2. Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Victoria Australia

3. Department of Urology The Royal Melbourne Hospital Parkville Victoria Australia

4. Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) and Molecular Imaging and Therapeutic Nuclear Medicine Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria Australia

5. Department of Urology University College London Hospitals Trust London UK

6. EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare Melbourne Victoria Australia

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15773

Reference6 articles.

1. AIHW.Australian Institute for Health and Welfare. Cancer in Australia 2021. Cancer series no. 133. Cat. no. CAN 144. [Internet].Australian Institute of Health and Welfare2021. Available from:https://www.aihw.gov.au/getmedia/0ea708eb‐dd6e‐4499‐9080‐1cc7b5990e64/aihw‐can‐144.pdf.aspx?inline=true. Accessed April 2022

2. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

3. Prospective, multisite, international comparison of 18 F‐fluoromethylcholine PET/CT, multiparametric MRI, and 68 Ga‐HBED‐CC PSMA‐11 PET/CT in men with high‐risk features and biochemical failure after radical prostatectomy: clinical performance and patient outcomes;Emmett L;J Nucl Med,2018

4. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy;European Urology Open Science;2023-07

2. Re‐defining ¹⁸F‐DCFPyl prostate‐specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology;BJU International;2023-06-12

3. Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?;BJU International;2023-05-16

4. Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer—A Prospective Cohort Study;Cancers;2022-12-13

5. Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference;Translational Andrology and Urology;2022-12